培菲康联合标准三联疗法根除幽门螺杆菌的临床分析

目的探讨联合应用培菲康在根除幽门螺杆菌（Hp）感染治疗中的临床应用价值。方法选取2012年5月至2014年8月期间诊治的H口感染患者，将符合纳入标准者（116例）随机分为A、B两组。A组（62例）为标准三联纽，给予奥美拉唑、克拉霉素、阿莫西林／甲硝唑三联疗法10d疗程。B组（54例）为联合培菲康组，在A组基础上加用培菲康。分别记录两组治疗前和治疗第11天有无腹痛、腹胀、恶心、呕吐、腹泻、胃纳减少、皮疹等7个主要临床指标变化情况。所有病例在治疗结束后4周统一行”C尿素呼气试验并记录Hp根除情况。结果两组7个主要临床观察指标中，除呕吐和皮疹2个指标发生率差异不显著（P〉0．05），其余5个指标B组中发生率明显低于A组（P均〈O．05）。治疗结束后4周B组中Hp根除率为84．8％，明显高于A组的68．7％（P〈0．01），OR值2．53（95％CI，1．51-4．12）。结论联合应hi培菲康能有效提高标准三联疗法Hp根除率，改善临床症状和减少药物不良反应。

Obejective To evaluate the effect of supplement of probiotics in the treatment of anti-Helicobacter Pylori （ Hp ） . Methods From May 2012 to August 2014, a total of 116 cases of patients with Hp infection who met with the inclusion criteria were randomly allocated to group A and B. Group A （ 62 cases ） was on standard triple Hp eradication therapy （ omeprazole, clarithromycin and amoxicillin/metronidazole ） for 10 days. Meanwhile Group B （ 54 cases ） was treated with probiotics combined with standard triple Hp eradication therapy. The change of 7 main clinical symptoms as abdominal pain, bloating, nausea, vomiting, diarrhea, appetite reduction and skin rashes in two groups were recorded respectively prior to and on the 1 lth day of the treatment. All patients were asked to take C13 urease breath test four weeks after the therapy to see the results of Hp eradication. Results Among 7 main clinical symptoms, except for vomiting and skin rashes, the occurrence rate of other 5 symptoms were significantly lower （ P〈0.05 ） in group A compared to group B. Four weeks follow-up after the therapy showed the eradication rates were significantly higher in group A （ 84.8% ） than in group B （ 84.8% ） （ P〈0.01 ） , OR value 2.53 （ 95%CI, 1.51-4.12 ） .Conclusions Administration of＇probiotics in standard triple therapy can effectively improve Helicobacter pylori eradication rates, ameliorate clinical symptoms and reduce adverse drug reactions.